Advances of next-generation immune checkpoint blockade / 国际肿瘤学杂志

ABSTRACT

Immune checkpoint blockades can induce long lasting responses but only in a fraction of patients owing to deficient of antibody as well as the neglect of immune suppressive cells.Next-generation immune checkpoint blockades,including FcγR-binding anti-programmed cell death-1 (PD-1)/PD ligand 1 (PD-L1) antibodies,co-inhibitors of immune checkpoint,small-molecule modulators and antibody-drugs conjugated with PD-1/PD-L1,will overcome the deficiencies of current anti-PD-1/PD-L1 antibodies and will become the direction of immunotherapy in the future.